- Subcutaneous tocilizumab in the treatment of rheumatoid arthritis +12014 | First Faculty of Medicine
- Tocilizumab in the treatment of rheumatoid arthritis2017 | First Faculty of Medicine
- Tocilizumab in the treatment of juvenile idiopathic arthritis2019 | Publication without faculty affiliation
- Tocilizumab in the treatment of giant cell arteritis2017 | Publication without faculty affiliation
- Long-term experience with therapeutic use of tocilizumab in rheumatoid arthritis2015 | First Faculty of Medicine
- The Tocilizumab2010 | First Faculty of Medicine
- Use of tocilizumab in subcutaneous form for the treatment of rheumatoid arthritis2015 | Third Faculty of Medicine
- Tocilizumab in the Treatment of Rheumatoid Arthritis2008 | First Faculty of Medicine
- Influence of tocilizumab treatment on depression symptoms in patients with rheumatoid arthritis2015 | First Faculty of Medicine
- Effect of tocilizumab in a patient with corticosteroid-resistant temporal arteritis2018 | First Faculty of Medicine
- Cardiovascular safety of tocilizumab therapy: results of the ENTRACTE Clinical Trial2018 | First Faculty of Medicine
- Tocilizumab treatment in rheumatoid arthritis2015 | First Faculty of Medicine, Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- What as the predictor factors for response to therapy with tocilizumab in real clinical practice? Experiences from national registry ATTRA2013 | First Faculty of Medicine
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis2012 | First Faculty of Medicine
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice2012 | First Faculty of Medicine
- Targeted inhibition of IL-6 signaling with tocilizumab improves quality of life and function in patients with rheumatoid arthritis with inadequate response to a range of DMARDs.Publication without faculty affiliation
- Tocilizumab v léčbě revmatoidní artritidy a systémové juvenilní idiopatické artritidy2012 | Third Faculty of Medicine
- Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice2019 | First Faculty of Medicine
- Safety of biological treatment – recommendations of Czech Society for Rheumatology.2009 | First Faculty of Medicine
- Inhibitor receptoru pro interleukin 6 tocilizumab - nová šance pro nemocné obrovskobuněčnou arteriitidou2019 | First Faculty of Medicine
- Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study2016 | First Faculty of Medicine
- Biological therapy in Rheumatology2016 | First Faculty of Medicine
- Temporal arteritis - pitfalls in diagnosis and treatment2019 | First Faculty of Medicine
- Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials2020 | First Faculty of Medicine
- Inhibice interleukinu 6 - moderní léčba obrovskobuněčné arteriitidy2017 | First Faculty of Medicine
- Present and future of biological therapies for rheumatoid arthritis - a dilemma of choice +12015 | Publication without faculty affiliation
- Postavení biologické terapie v léčbě revmatoidní artritidy2015 | First Faculty of Medicine
- Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis2016 | First Faculty of Medicine